Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$86.88 USD

86.88
213,105

+2.51 (2.97%)

Updated Jul 8, 2024 04:00 PM ET

After-Market: $86.88 0.00 (0.00%) 7:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer

by Zacks Equity Research

Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.

Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection

by Zacks Equity Research

Gilead's (GILD) twice-yearly, subcutaneous lenacapavir has demonstrated its potential as a new tool to help prevent HIV infections with zero infections and 100% efficacy. Shares gain.

Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics

by Zacks Equity Research

Roche (RHHBY) gets exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million.

Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?

by Zacks Equity Research

Terns Pharmaceuticals, Inc. (TERN) outperforms the industry year to date on encouraging pipeline progress of its oncology candidate.

Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study

by Zacks Equity Research

Roche's (RHHBY) Columvi significantly extends survival in patients with relapsed or refractory diffuse large B-cell lymphoma in the phase III STARGLO study.

Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment

by Zacks Equity Research

Amgen's (AMGN) Blincyto is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-ALL in the consolidation phase, regardless of MRD status.

Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro

by Zacks Equity Research

The FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.

Shattuck (STTK) Announces Positive Interim Data on Cancer Drug

by Zacks Equity Research

Shattuck (STTK) will now focus on higher-risk myelodysplastic syndromes and TP53 mutant acute myeloid leukemia indications for lead candidate SL-172154, following encouraging interim data from the phase IB dose expansion study.

What Makes Ligand (LGND) a New Strong Buy Stock

by Zacks Equity Research

Ligand (LGND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Compelling Reasons to Hold on to HCA Healthcare (HCA) Stock

by Zacks Equity Research

HCA Healthcare (HCA) remains well-poised for growth on the back of improved revenues, a well-diversified healthcare portfolio and solid cash-generating abilities.

Why Is Ligand (LGND) Up 4% Since Last Earnings Report?

by Zacks Equity Research

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

New Strong Buy Stocks for June 6th

by Zacks Equity Research

HWM, LGND, MATX, SMFKY and HAE have been added to the Zacks Rank #1 (Strong Buy) List on June 6, 2024.

Ensign Group (ENSG) Buys Facilities in Arizona & Colorado

by Zacks Equity Research

Ensign Group (ENSG) expands its footprint by acquiring skilled nursing facilities in Arizona and Colorado, enhancing its healthcare services and real estate portfolio.

Does Ligand (LGND) Have the Potential to Rally 32.33% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 32.3% in Ligand (LGND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Recent Price Trend in Ligand (LGND) is Your Friend, Here's Why

by Zacks Equity Research

Ligand (LGND) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo

by Zacks Equity Research

The FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).

AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030

by Zacks Equity Research

AstraZeneca (AZN) targets $80 billion in total revenues by 2030. It expects to launch 20 new medicines.

Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies

by Zacks Equity Research

Dyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage studies evaluating DYNE-101 and DYNE-251 for different muscle disease indications.

PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug

by Zacks Equity Research

PTC Therapeutics (PTCT) gains 21% on May 20 after the EC decided against adopting the negative CHMP opinion of January 2024 on the annual renewal of the conditional approval of Translarna.

Vertex (VRTX) Outperforms Industry on Rapid Pipeline Progress

by Zacks Equity Research

While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.

Roche (RHHBY) Cancer Drug Gets Breakthrough Therapy Designation

by Zacks Equity Research

Roche's (RHHBY) inavolisib gets Breakthrough Therapy Designation in the United States for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla

by Zacks Equity Research

Exelixis (EXEL) resolves two patent litigations and grants Cipla a license to market generic versions of Cabometyx in the United States beginning January 2031.

BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why

by Zacks Equity Research

Beigene's (BGNE) shares surge 32% in a month due to the label expansion of one of its key oncology drugs, Tevimbra, to treat three NSCLC indications, including first- and second-line use, in the EU.

Gilead (GILD) Announces Positive Interim Results on PBC Drug

by Zacks Equity Research

Gilead Sciences (GILD) experimental candidate, seladelpar, demonstrates significant improvements in liver disease progression and reduced itching in primary biliary cholangitis study.

Here's Why Merck (MRK) Stock Has Outperformed Industry YTD

by Zacks Equity Research

Merck (MRK) stock is being driven by the strong sales of key products like Keytruda and Gardasil and positive pipeline and regulatory developments.